Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Angers – page 45

676 clinical trials in Angers, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Angers at a glance
676
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

676 trials in Angers

Open in trial search

Bladder cancer

Not recruiting

Study on the Effectiveness and Safety of Durvalumab with Gemcitabine and Cisplatin for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab with Platinum-Based Chemotherapy for Patients with Early-Stage Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Not recruiting

Study on Luspatercept for Treating Anemia in Adults with Myelofibrosis on JAK2 Inhibitor Therapy Requiring Red Blood Cell Transfusions

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Thrombotic microangiopathy

Not recruiting

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Metabolic dysfunction-associated liver disease

Not recruiting

Study on GSK4532990 for Adults with Nonalcoholic Steatohepatitis (NASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Gsk4532990A
  • Sponsor:Glaxosmithkline Research & Development Limited

HER2 positive breast cancer

Not recruiting

Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Colorectal cancer metastatic

Not recruiting

Comparing drug combinations with panitumumab for patients with RAS and B-RAF wild-type metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Unicancer

Breast cancer metastatic

Not recruiting

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer+3

Not recruiting

Study on Chemotherapy with Paclitaxel, Cisplatin, and Carboplatin for Patients with Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Transitional cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer After Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mrna-4157
  • Sponsor:Merck Sharp & Dohme LLC

Amyotrophic lateral sclerosis

Not recruiting

Study on the Effects of NX210c and Glucose in Adults with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Axoltis Pharma

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Angers

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple myeloma, breast cancer, and various forms of lung cancer. Studies are evaluating new combination therapies and treatment approaches for both early-stage and advanced cancers.

  • Triple-negative breast cancer treatments
  • Advanced non-small cell lung cancer therapies
  • Head and neck squamous cell carcinoma studies

Research includes investigation of novel drug combinations and immunotherapy approaches.

02 Cardiovascular Studies

Clinical research addressing heart failure prevention and acute myocardial infarction management. Studies are exploring innovative pain management approaches and preventive treatments.

  • Heart failure risk reduction
  • Pulmonary hypertension treatments
  • Emergency cardiac care interventions

Focus on both acute care solutions and long-term prevention strategies.

03 Immunology and Transplantation

Comprehensive research in kidney transplantation and immune disorders, including studies on preventing rejection and managing immunosuppression.

  • Transplant rejection prevention
  • Immune response monitoring
  • Novel immunotherapy approaches

Trials aim to improve long-term outcomes for transplant recipients and immune disorder patients.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.